Compare VRCA & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | AMWL |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.5M | 91.2M |
| IPO Year | 2018 | 2020 |
| Metric | VRCA | AMWL |
|---|---|---|
| Price | $5.54 | $12.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.00 | $7.40 |
| AVG Volume (30 Days) | 36.0K | ★ 105.5K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $94.44 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $3.28 | $3.71 |
| 52 Week High | $9.82 | $11.45 |
| Indicator | VRCA | AMWL |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 79.74 |
| Support Level | $5.32 | $8.25 |
| Resistance Level | $6.60 | N/A |
| Average True Range (ATR) | 0.47 | 0.78 |
| MACD | -0.07 | 0.31 |
| Stochastic Oscillator | 22.10 | 96.41 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.